Table 1.
Baseline characteristics of patients and clinical response to the docetaxel plus carboplatin regimen.
| Patient and disease feature from the diagnostic core | N = 9 (%) |
|---|---|
| Age (year) | |
| ˂50 | 4 (45%) |
| ≥ 50 | 5 (55%) |
| Menopausal status | |
| Pre | 4 (45%) |
| Post | 5 (55%) |
| Clinical T-stage | |
| T1 | 1 (11%) |
| T2 | 5 (55%) |
| T3 | 2 (23%) |
| T4 | 1 (11%) |
| Clinical N-stage | |
| N0 | 2 (23%) |
| N1 | 6 (66%) |
| N2 | 1 (11%) |
| N3 | 0 (0%) |
| Symmans class | |
| pCR | 3 (33%) |
| RCB-I | 1 (11%) |
| RCB-II | 3 (33%) |
| RCB-III | 2 (23%) |
| Clinical response (MRI) | |
| Complete response | 2 (23%) |
| Minor response | 5 (55%) |
| Partial response | 1 (11%) |
| Progression disease | 0 (0%) |
| Stable disease | 1 (11%) |
| Ki 67 expression | |
| ˂50 | 1 (11) |
| ≥ 50 | 8 (89%) |
| Histologic grade | |
| G1 | 0 (0%) |
| G2 | 2 (23%) |
| G3 | 6 (64%) |
| No data | 1 (11%) |
| Germline homologous recombination mutation | |
| BRCA wt | 6 (66%) |
| BRCA mut | 2 (22%) |
| PALB2 mut | 1 (11%) |
| Current status (the last follow-up date) | |
| Recurrence and death | 2 (22%) |
| Recurrence and alive | 1 (11%) |
| Alive and no recurrence | 6 (66%) |
MRI magnetic resonance imaging, pCR pathological clinical response, RCB residual cell burden, T tumor, N nodes, G grade.